Shares of HeartBeam, Inc. (NASDAQ:BEAT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $4.00.
A number of equities analysts have recently commented on BEAT shares. Wall Street Zen raised shares of HeartBeam from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartBeam in a research note on Thursday, July 2nd. Maxim Group initiated coverage on shares of HeartBeam in a research report on Tuesday, July 14th. They set a “buy” rating and a $2.00 price objective on the stock. Benchmark dropped their price objective on shares of HeartBeam from $8.00 to $5.00 and set a “speculative buy” rating on the stock in a research note on Friday, May 15th. Finally, HC Wainwright reduced their target price on shares of HeartBeam from $5.50 to $2.50 and set a “buy” rating for the company in a report on Friday, May 22nd.
Check Out Our Latest Research Report on BEAT
Institutional Trading of HeartBeam
HeartBeam Stock Down 4.0%
NASDAQ:BEAT opened at $0.48 on Wednesday. The stock’s 50 day moving average price is $0.62 and its 200 day moving average price is $0.96. The company has a market capitalization of $26.65 million, a PE ratio of -0.94 and a beta of -0.78. HeartBeam has a 52-week low of $0.48 and a 52-week high of $4.00.
HeartBeam (NASDAQ:BEAT – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, sell-side analysts anticipate that HeartBeam will post -0.38 EPS for the current fiscal year.
HeartBeam Company Profile
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.
Featured Stories
- Five stocks we like better than HeartBeam
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for HeartBeam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartBeam and related companies with MarketBeat.com's FREE daily email newsletter.
